Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 23Active not recruiting 4Recruiting 3Withdrawn 2Terminated 2Unknown 1

Sponsor Class

OTHER 29NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma 1

Interventions

Cisplatin 14Radiotherapy 13Oxaliplatin 8Fluorouracil 7Gemcitabine 6Drug Therapy 6Leucovorin 5Doxorubicin 5Cytarabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5durvalumab 4Paclitaxel 4Etoposide 4Docetaxel 4Chemotherapy, Adjuvant 4Biological Therapy 4bicalutamide 3Rituximab 3Radiotherapy, Intensity-Modulated 3Polymerase Chain Reaction 3Platinum 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Gene Expression Profiling 3Dexamethasone 3Bortezomib 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × Melphalan × Clear all
NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡